Ascletis Pharma, ASC50, Plaque Psoriasis, IL-17A Inhibitor, Oral Small Molecule, Clinical Trial, Phase I

Hong Kong, September 29, 2026 Ascletis Pharma Inc. announced positive results from a randomized, double-blind, placebo-controlled 28-day proof-of-concept clinical...